MaxCyte (MXCT): Utang-utang marang kapitalisasi buku

Tandha merek MaxCyte, Inc (MXCT)

MaxCyte, Inc. (MXCT) faces risks due to potential cuts in partner innovation spending and pressure from corporate in-house development departments. Meanwhile, experienced management is effectively selling access to its platform, demonstrating strict operational control. Growth relies on expanding the network of B2B contracts with pharma behemoths, and the indicator stands at 0.11. This chart of the current share price clearly illustrates the company's market dynamics.

MXCT Rasio utang marang nilai buku MaxCyte, Inc. (04.07.2022 - 26.10.2026)

Ringkesan rincian data analitis MaxCyte Inc. (MXCT)

- rega lan prakiraan konsensus rega:
Rega saham MaxCyte, Inc.|MXCT - Prakiraan konsensus analis
- data kapitalisasi pasar:
Kapitalisasi pasar MaxCyte Inc|MXCT - Nilai Perusahaan Nalika Diakuisisi Penuh
- data kapitalisasi buku:
Aset Bersih saben Siji Saham MaxCyte|MXCT - Kapitalisasi Akuntansi|Rasio Nilai Pasar marang Nilai Buku maxcyte.com|MXCT - Aset Perusahaan
- data utang lan likuiditas:
Utang marang Ekuitas MaxCyte, Inc.|MXCT - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas MaxCyte, Inc|MXCT - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku MaxCyte Inc
Analisis fundamental perusahaan:MaxCyte, Inc.
Produk merek MaxCyte Inc

To select the most resilient assets, investors utilize financial leverage filtering to assess a business's dependence on external loans. This metric compares total debt to the book value of equity, allowing this chart of the debt-to-equity ratio to evaluate the risks facing MaxCyte, Inc. (MXCT) as it scales its intelligent software and automates the production of precision systems.

Pesaing MaxCyte, Inc.

Utang-utang marang kapitalisasi buku ABT (Abbott Laboratories)|Utang-utang marang kapitalisasi buku thermofisher.com TMO|Utang-utang marang kapitalisasi buku GEHC|MTD: Utang marang aset resik|Rasio utang marang kapitalisasi buku Waters Corp.|TECH (Bio-Techne Inc.) - Rasio utang marang nilai buku|Rasio utang marang kapitalisasi buku BRKR (Bruker Corporation)|Utang-utang marang nilai buku AZTA|VREX (Varex Imaging Corporation) - Rasio utang marang kapitalisasi buku|Utang-utang marang aset resik Semler Scientific Inc SMLR|Utang marang nilai buku Butterfly iQ (BFLY)|Utang marang modal buku Mesa Laboratories Corp. MLAB|Utang-utang marang kapitalisasi buku QSI (Quantum-Si)|NNOX - Utang-utang marang aset resik|QTRX (Quanterix) - Utang-utang marang kapitalisasi buku|Utang marang nilai buku 908 Devices Inc|CV - Utang marang nilai buku|Rasio utang marang aset resik RPID|Rasio utang marang kapitalisasi buku SEER (Seer, Inc.)|Utang marang nilai buku hyperfine.io (HYPR)|FONR: Utang-utang marang kapitalisasi buku|Utang-utang marang nilai buku Daxor Corp DXR|Spectral AI (MDAI) - Utang-utang marang kapitalisasi buku|VIVS - Rasio utang marang nilai buku|Aclarion - Utang-utang marang kapitalisasi buku|Akoya Biosciences, Inc. (AKYA) - Utang-utang marang aset resik|Utang-utang marang kapitalisasi buku THMO|Utang marang nilai buku Talis Biomedical Corp|Utang-utang marang kapitalisasi buku TTOO